BEIJING: CanSino Biologics Inc says it has received Chinese regulatory approval to start human trials of a vaccine against Covid-19, another example of a potential weapon against the illness being fast-tracked for testing as the global death toll escalates and nations impose lockdowns on their citizens.
The vaccine, co-developed by the Hong Kong-listed company and China’s Academy of Military Medical Sciences, will undergo clinical trials in Wuhan, CanSino Biologics said in a statement to the Hong Kong Stock Exchange yesterdat.Wuhan is the epicentre for the pandemic that has spread to all corners of the planet, infecting more than 190,000 people and killing more than 7,800.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
